The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 01, 2022
Filed:
Jan. 08, 2019
Applicant:
Del Mar Pharmaceuticals (Bc) Ltd., Vancouver, CA;
Inventors:
Assignee:
Del Mar Pharmaceuticals (BC) Ltd., Vancouver, CA;
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/48 (2006.01); G01N 33/50 (2006.01); A61K 31/336 (2006.01); A61K 31/495 (2006.01); A61K 31/047 (2006.01); C12Q 1/6886 (2018.01); A61K 47/54 (2017.01); A61K 47/59 (2017.01); A61K 47/62 (2017.01); A61K 31/4188 (2006.01); A61K 45/06 (2006.01); A61N 5/10 (2006.01);
U.S. Cl.
CPC ...
A61K 31/336 (2013.01); A61K 31/047 (2013.01); A61K 31/4188 (2013.01); A61K 31/495 (2013.01); A61K 45/06 (2013.01); A61K 47/542 (2017.08); A61K 47/593 (2017.08); A61K 47/62 (2017.08); A61N 5/1007 (2013.01); C12Q 1/6886 (2013.01); A61K 2300/00 (2013.01); A61N 5/10 (2013.01); A61N 2005/1024 (2013.01); A61N 2005/1098 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/154 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01);
Abstract
The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.